Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Pfizer said Tuesday that it will purchase Biohaven, a maker for migraine drugs, for $11.6 billion in cash in a deal that may help ease what has been a brutal bear market for biotechnology stocks. → Read More
DNA sequencing giant Illumina announced that it would enter the field of drug discovery, a major shift for a company that, since its founding in 1998, has thrived instead by selling picks and shovels to the prospectors of biotech’s various gold rushes. → Read More
Gilead's Dan O’Day has charisma and charm. What he lacks lately are clear wins in drug development. → Read More
Plans to attempt to authorize the Pfizer/BioNTech Covid vaccine for children under 5 before full data are available appear to have run aground. → Read More
The resignation of Eric Lander as President Biden’s lead scientific adviser is not just a blow to one president’s plans for advancing research, but a signpost on the death march of a certain way of doing science. → Read More
Biosplice, once the world’s most valuable biotech startup, is laying off nearly a quarter of its workforce. → Read More
Pfizer, the company behind a Covid vaccine and a Covid pill, has named a new top development executive as Covid remakes the company. → Read More
Biotech investors, once the envy of Wall Street, have slipped into despondency. After a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. → Read More
Pfizer expects initial findings from the study, which will enroll 1,420 volunteers in three cohorts, to be available during the first half of 2022. How soon regulators could authorize an Omicron-specific vaccine is unclear. → Read More
Hal Barron was hired to turn around R&D at GSK four years ago. Did he accomplish his mission? → Read More
A team of biotech veterans say they have raised $3 billion to create a continent-spanning company that will aim to battle disease by reprogramming the fundamental machinery of living cells. It appears to be the largest venture capital fundraising effort in biotech history, based on a survey of data from Pitchbook. → Read More
A new study raises significant doubts about whether at-home rapid antigen tests can detect the Omicron variant before infected people can transmit the virus to others. → Read More
The FDA granted emergency authorization to Merck’s molnupiravir, an antiviral pill shown to reduce hospitalization and death in cases of Covid-19, the second such treatment to be authorized. → Read More
The FDA granted emergency authorization to Merck’s molnupiravir, an antiviral pill shown to reduce hospitalization and death in cases of Covid-19, the second such treatment to be authorized. → Read More
The Food and Drug Administration on Wednesday authorized Paxlovid, a pill developed and made by Pfizer, as a treatment for Covid-19, a significant step in the battle against the SARS-CoV-2 virus. → Read More
Johnson & Johnson’s Covid vaccine was going to be the shot for the world. Now, under the weight of a mountain of bad PR, one wonders if the world will want it. → Read More
In a 2,246-patient study, Pfizer's Covid pill retained the efficacy at preventing hospitalization and death it had shown in an interim study. → Read More
STAT spoke with Pfizer’s head of vaccine research, Kathrin Jansen, about the latest data on the company's vaccine and Omicron. → Read More
The merger combines a hospital system known for research with one better known for aggressive marketing of its services. → Read More
A panel of experts convened by the FDA voted by a slim margin to recommend the agency authorize the Covid treatment developed by Merck and partner Ridgeback Biotherapeutics. → Read More